杠杆(统计)
计算机科学
机器学习
灵敏度(控制系统)
人工智能
源代码
水准点(测量)
计算生物学
钥匙(锁)
鉴定(生物学)
精密医学
抗药性
药物发现
计算模型
特征(语言学)
编码(集合论)
抗癌药
吉非替尼
数据挖掘
系统生物学
生物信息学
生物信息学
药品
传感器融合
抗癌药物
计算科学与工程
信息融合
抑制器
作者
NAN SHENG,Yunzhi Liu,Ling Gao,Wenju Hou,Lan Huang,Yan Wang
标识
DOI:10.1371/journal.pcbi.1013968
摘要
MicroRNAs (miRNAs) are pivotal regulators of drug resistance and sensitivity in cancer cells, functioning as tumor suppressors or oncogenes that modulate the cellular response to anticancer drugs. While experimental identification of miRNA-mediated drug resistance and sensitivity is both costly and laborious, computational methods present a promising alternative. Recent advances in pre-trained language models (PLMs) offer new opportunities to leverage large-scale unlabeled biomolecular data for enhanced relationship prediction. In this study, we introduce PLMF-MDA, a PLM-based cross-modal fusion model designed to predict miRNA-drug resistance (MDR) and miRNA-drug sensitivity (MDS) associations. PLMF-MDA integrates miRNA and drug multimodal embeddings derived from PLMs and intrinsic feature extractors, and employs a cross-modal attention fusion module to adaptively capture key interactions between modalities. To evaluate the performance of the approach, we manually constructed two benchmark datasets. Experimental results demonstrate that the PLMF-MDA achieves superior prediction performance. Furthermore, case studies on anticancer drug docetaxel and gefitinib demonstrate its potential in discovering novel MDR (MDS) associations. All data and source code are available on GitHub: https://github.com/sheng-n/PLMF-MDA.
科研通智能强力驱动
Strongly Powered by AbleSci AI